# 5-Amino-1MQ: The NNMT Inhibitor That Stacks With GLP-1s and MOTS-C
> Note: PeptIQ is not a medical provider. This article is for educational purposes only. Consult a qualified healthcare professional before starting any peptide or research compound protocol.
Most compounds in the fat-loss space work through one of two levers: appetite suppression or increased energy expenditure. GLP-1 agonists like Retatrutide are exceptional at the first. MOTS-C improves the second at the cellular level.
5-Amino-1MQ works through a third lever that most people haven't thought about — and that's exactly why it stacks so well with both.
What Is 5-Amino-1MQ?
5-Amino-1MQ (5-amino-1-methylquinolinium) is a selective inhibitor of NNMT — nicotinamide N-methyltransferase. That enzyme name sounds technical, but its role in fat metabolism is surprisingly straightforward once you understand it.
NNMT's job: Take nicotinamide (a NAD+ precursor) and methylate it — essentially tagging it for disposal. The more NNMT activity, the more your NAD+ precursors get converted into a form your cells can't use.
5-Amino-1MQ's job: Block NNMT. This does two things:
- Keeps NAD+ precursors available for actual NAD+ synthesis
- Depletes the methyl groups that fat cells use to maintain their metabolic "off" state
- Animals treated with 5-Amino-1MQ lost significant fat mass compared to controls
- Effects were most pronounced in visceral adipose tissue — the metabolically dangerous fat around organs
- No cardiovascular toxicity or significant off-target effects were observed at research doses
- Body weight decreased without appetite changes, suggesting the mechanism was purely metabolic
- Week 1–4: Establish Reta (or Tirz) baseline. Get titration dialed in.
- Week 5: Add MOTS-C (250mcg/day, ramp to 500mcg/day over 2 weeks) + NAD+ (250–500mg/day NMN or NR). These two can start simultaneously — NAD+ does not need to be loaded first.
- Week 7–8: Add 5-Amino-1MQ (5mg/day to start, increase to 10–25mg/day based on tolerance)
- MOTS-C: mild energy changes weeks 1–2, more noticeable improvement by week 3–4
- 5-Amino-1MQ: subtle metabolic shift, most noticeable when combined with consistent Zone 2 cardio
- NAD+: gradual energy improvement, not stimulant-like
- Reta: once weekly subQ
- MOTS-C: 500mcg/day subQ, morning fasted or pre-workout
- NAD+ (NMN/NR): morning with food
- 5-Amino-1MQ: morning, fasted or with NAD+ supplement
- A replacement for GLP-1 therapy
- A stimulant
- A well-studied human compound (animal data only for the fat loss mechanism)
- Something to stack recklessly at high doses without bloodwork
The second effect is the more interesting one. White adipose tissue — particularly visceral fat — uses a high-NNMT/low-NAD+ state to stay metabolically dormant. When NNMT is blocked, these fat cells shift toward a more metabolically active phenotype. In animal models, this translated to meaningful reductions in fat mass without changes in food intake.
The Research Behind It
The foundational work on 5-Amino-1MQ came from the Yoon lab at the University of Texas. In obese mouse models:
Human data is limited — this is still a research compound. But the mechanism is well-characterized and the target (NNMT in adipose tissue) is a legitimate pathway for visceral fat reduction.
Why It Pairs So Well With GLP-1 Agonists
GLP-1 agonists like Retatrutide create a caloric deficit through multiple routes: appetite suppression, slowed gastric emptying, and (in Reta's case) glucagon receptor agonism that drives additional energy expenditure. You're eating less and burning more.
The problem with prolonged caloric deficit is that metabolic adaptation — your body downregulates energy expenditure over time to resist the deficit.
5-Amino-1MQ addresses a specific piece of that adaptation: the fat cell's tendency to become increasingly metabolically dormant as weight loss continues. By blocking NNMT, you're keeping visceral fat cells in a more reactive state even as overall caloric restriction continues.
Practical result: Better visceral fat targeting during GLP-1 protocols, particularly in the later phases when the easy fat has already come off.
The MOTS-C Connection
MOTS-C activates AMPK through a mitochondrial stress pathway, improving fat oxidation and cellular energy efficiency. One of MOTS-C's downstream effects is increasing intracellular NAD+ utilization — the mitochondria are running harder, so they're consuming more of the NAD+ pool.
5-Amino-1MQ complements this by ensuring that pool stays replenished. NNMT normally burns through NAD+ precursors as a kind of metabolic "bleed." Block the bleed, and MOTS-C's expanded mitochondrial activity has more substrate to work with.
Some community members are running this sequence deliberately: start with NAD+ precursors (NMN/NR) to raise the baseline pool, then add MOTS-C to put that pool to work, then layer in 5-Amino-1MQ to block the pathway that drains it. The logic is solid, though it's worth noting this is a community-derived protocol, not a studied stack.
How to Dose 5-Amino-1MQ
5-Amino-1MQ is an oral compound. It is not a peptide, and there is no injectable form with established safety data — oral is the right route.
Standard research dose: 5–25mg/day oral
Timing: Morning, pre-cardio or fasted
Cycling: 8–12 weeks on / 4 weeks off is a reasonable protocol based on general NNMT inhibitor principles
Form: Most sources provide capsules or powder; capsules are easier for consistent dosing
Note on higher doses: Some researchers in the community are experimenting with significantly higher doses (100–300mg+). The reasoning is that oral bioavailability is ~40–50%, and animal study HED conversions suggest higher doses may be needed for the full effect. This is exploratory territory — if you go higher, do it with bloodwork monitoring and go slowly.
Stacking with NMN/NR: If you're running NAD+ precursors alongside 5-Amino-1MQ, standard doses of NMN or NR (250–500mg/day) are appropriate. No dose adjustment needed.
Full Stack Protocol: Reta + MOTS-C + NAD+ + 5-Amino-1MQ
For people on GLP-1 agonists looking to optimize body recomposition:
Layering sequence (if starting from scratch):
Running simultaneously (established protocol):
If you're already on GLP-1 therapy and want to add the full stack, all four can be added simultaneously. Watch for:
Timing:
What to Realistically Expect
5-Amino-1MQ is not a dramatic compound. It won't produce the obvious appetite suppression of Reta or the noticeable energy shift of MOTS-C. Most people running it describe the effect as "things just working a bit better" — particularly for visceral fat reduction that plateaued on GLP-1 therapy alone.
If you're deep into a Reta protocol and your overall weight is moving but the midsection stubborn fat isn't shifting, this is a reasonable addition to explore.
What This Isn't
5-Amino-1MQ is not:
The mechanism is legitimate and the animal data is compelling. But the human data gap is real. Treat it as what it is: an experimental add-on to a well-designed protocol, not a foundational compound.
FAQ
Q: Do I need to be on a GLP-1 to use 5-Amino-1MQ?
No — but the stack logic is strongest when combined with a GLP-1 agonist creating a caloric deficit. Standalone 5-Amino-1MQ without dietary or pharmacological caloric reduction will have more modest effects.
Q: Can I stack 5-Amino-1MQ with Tesamorelin?
Yes — no known interactions. Tesamorelin (a GHRH analog) targets visceral fat through the GH/IGF-1 axis; 5-Amino-1MQ targets it through NNMT inhibition. Different mechanisms, complementary effects.
Q: Will I lose muscle on this stack?
No. 5-Amino-1MQ's mechanism is specific to fat cell metabolism. MOTS-C is actively muscle-preserving through AMPK. GLP-1 agonists can cause some muscle loss if protein intake is insufficient — ensure you're hitting 180–200g protein/day.
Q: Is there a better oral source vs capsule for absorption?
Both work. Some people use sublingual delivery (powder held under the tongue briefly before swallowing) but there's no strong evidence this meaningfully improves bioavailability for this compound class. Capsules are simpler and more consistent.
Q: Can women use 5-Amino-1MQ?
Yes — the NNMT pathway is not sex-specific. Women running GLP-1 protocols have used it with the same general approach as men. Hormonal interactions are not a documented concern at research doses.
---
Track Your Protocol
Running four compounds simultaneously is where tracking becomes essential. Without a log, you're guessing which compound is doing what. PeptIQ lets you track daily doses, timing, energy levels, recovery, and body composition so the data tells you what's actually working.
Download PeptIQ — free to start.
